Published online before print January 6, 2003, doi: 10.1161/01.CIR.0000047280.15244.EB
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;107:571.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
Myocardial Production of C-Type Natriuretic Peptide in Chronic Heart Failure
From Clinical Cardiology (P.R.K., A.P.B., S.D.A., P.A.P.-W., A.J.C.), National Heart and Lung Institute, London, UK; Royal Brompton Hospital (J.R.C.), London, UK; Department of Cardiology (S.D.A.), Charité, Berlin, Germany; and Clinical Pharmacology and Therapeutics (A.D.S.), University of Dundee, UK.
Correspondence to Paul R. Kalra, Clinical Cardiology, NHLI, Dovehouse St, London SW3 6LY, UK. E-mail p.kalra{at}ic.ac.uk
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— C-type natriuretic peptide (CNP) is a vasodilator produced by the vascular endothelium. It shares structural and physiological properties with the cardiac hormones atrial natriuretic peptide and brain natriuretic peptide (BNP), but little is known about its pathophysiological role in chronic heart failure (CHF). We assessed the hypothesis that CNP is produced by the heart in patients with CHF.
Methods and Results— Myocardial CNP production was determined (difference in plasma levels between the aortic root and coronary sinus [CS]) in 9 patients undergoing right and left heart catheterization as part of their CHF assessment (all male, age 59±9 years; New York Heart Association class 2.2±0.1; left ventricular ejection fraction 29±5%; creatinine 105±8 µmol/L [all values mean±SEM]). BNP, established as originating from myocardium, was assessed from the same samples as a positive control. Analyses were performed by a blinded operator using a standard competitive radioimmunoassay kit (Peninsula Laboratories, Bachem Ltd UK). A step-up (29%) in plasma CNP concentration was found from the aorta to the CS (3.55±1.53 versus 4.59±1.54 pg/mL, respectively; P=0.035). The mean increase in CNP was 0.90±0.35 pg/mL (range 0.05 to 2.80 pg/mL). BNP levels increased by 57% from aorta to CS (86.0±20.5 versus 135.0±42.2 pg/mL; P=0.01). CS CNP levels correlated with mean pulmonary capillary wedge pressure (r=0.82, P=0.007).
Conclusions— We have shown that CNP is produced by the heart in patients with CHF. Although further evaluation is required to define its full pathophysiological role in this condition, CNP may represent an important new local mediator in the heart.
Key Words: heart failure • hormones • myocardium • natriuretic peptides
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
C-type natriuretic peptide (CNP) is a vasodilator produced by the vascular endothelium.1 Although it shares structural and physiological properties with the cardiac hormones atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP),2 it has a much shorter circulatory half-life.3 Considerable evidence supports a central pathophysiological role for ANP and BNP in cardiovascular disease, and in particular chronic heart failure (CHF).4,5 In contrast, little is known about the role of CNP in this condition.
Studies with myocardial tissue have demonstrated mRNA transcripts for the CNP receptor,6 prompting speculation that CNP may have a role in the control of cardiac function. Wei and colleagues7 subsequently confirmed the presence of CNP within myocardium by immunohistochemistry and radioimmunoassay. In vitro studies have shown that CNP can influence myocardial function.8,9 CNP may therefore represent an important new mediator in the heart. In the present study, we assessed the hypothesis that CNP is produced by the heart in patients with CHF.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Ten patients undergoing right and left heart catheterization as part of their CHF assessment were recruited. The diagnosis of heart failure was based on symptoms, examination, and appropriate investigations (chest radiograph, echocardiogram, and cardiac MRI). All patients had evidence of left ventricular (LV) dilatation (LV end-diastolic dimension
60 mm). Myocardial CNP production was determined from the difference in plasma levels between the aortic root and coronary sinus (CS). BNP, established as originating from myocardium,5 was assessed from the same samples to serve as a positive control. It was technically not possible to cannulate the CS in 1 patient; data are presented for the remaining 9 patients (all male, age 59±9 years; New York Heart Association class 2.2±0.1; Table). No patient had significant renal failure (creatinine 105±8 µmol/L) or active infection/inflammation. Patients were receiving conventional medication for heart failure: ACE inhibitor or angiotensin II receptor blocker (n=9), diuretics (n=7), and ß-blockers (n=4). Ethical approval was granted by the local ethics committee. Written informed consent was obtained from all participants.
|
After confirmation of the catheter position by fluoroscopy (advanced past the CS ostium), blood was collected into chilled EDTA tubes containing aprotinin. Samples were immediately centrifuged for 15 minutes at 3000 rpm, and the plasma phase was stored at -80°C. CNP and BNP measurements were performed by a blinded operator using standard competitive radioimmunoassay kits (Peninsula Laboratories, Bachem Ltd UK) after solid phase extraction from plasma proteins as described previously.10 The intra-assay coefficient of variation was 11.4% for CNP and 12.2% for BNP. The anti-CNP antibody used had no cross-reactivity with human ANP or BNP, and the specific rabbit antiserum for human BNP-32 had no cross-reactivity with human ANP or CNP. The lower limit of detection for both peptide assays is 0.1 pg/mL.
Statistics
Data were analyzed with StatView 4.5 (Abacus Concepts Inc) and are expressed as mean±SEM. Because of the skewness of CNP levels, a logarithmic transformation was used. Differences between sample sites were assessed by paired t test. Simple regression analysis was performed. A probability value of <0.05 was considered statistically significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Patients had evidence of LV dysfunction (LV end-diastolic dimension 67±3 mm, ejection fraction 29±5%, and pulmonary capillary wedge pressure [PCWP] 19±2 mm Hg). A significant step-up (29%) in plasma CNP concentration was found from the aorta to the CS (3.55±1.53 versus 4.59±1.54 pg/mL, respectively; P=0.035; Figure 1 and the Table). The mean increase in CNP was 0.90±0.35 pg/mL (range 0.05 to 2.80 pg/mL). A mean increase in plasma BNP of 49.1±28.9 pg/mL (57%) was seen when levels in the aorta were compared with those in the CS (86.0±20.5 versus 135.0±42.2 pg/mL, respectively, P<0.05).
|
Relationship of CS CNP Levels to Clinical Variables
A significant correlation was found between mean PCWP and CS CNP levels (r=0.82, P<0.007; Figure 2) but not aortic CNP levels (P>0.15). No relationship was found with pulse rate, blood pressure, or LV ejection fraction or end-diastolic dimension (all P>0.09). The relationship between CS levels of CNP and BNP just failed to reach significance (r=0.62, P=0.07).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The central role of neurohormones, including ANP and BNP, in the pathophysiology of heart failure is firmly established.11 The role of CNP, however, has not been determined. It is generally thought that CNP, a vasorelaxant,1 originates from vascular endothelium.12 The biological actions of the natriuretic peptides are mediated through specific receptors (NPR) and a resulting elevation in intracellular cGMP. Several receptor subtypes exist, and NPR-B is more specific for CNP.13 The finding of high levels of NPR-B in vascular smooth muscle and the observation that CNP inhibits local vascular ACE14 have fueled speculation that CNP plays an important role in local vascular regulation.
Plasma CNP levels are not elevated in patients with stable CHF.7,10 In view of the short plasma half-life of CNP, circulating levels may not reflect tissue concentrations near the site of production. Natriuretic peptides are catabolized by 2 distinct mechanisms. NPR-C is thought to act as a clearance receptor; after binding of a natriuretic peptide to NPR-C, the resulting receptor-ligand complex undergoes endocytosis and subsequent lysosomal hydrolysis.15 The second route of elimination involves cleavage by neutral endopeptidase. This enzyme has a wide tissue distribution, including the vascular endothelium.16 In vitro, CNP appears to be particularly sensitive to hydrolysis by neutral endopeptidase.17
Early studies failed to detect CNP mRNA within human myocardium.18 Interest was renewed when mRNA transcripts for NPR-B were found within myocardial tissue, prompting speculation that CNP may influence cardiac function.6 Wei and colleagues7 confirmed the presence of CNP within atrial and ventricular myocardium by immunohistochemistry and radioimmunoassay; myocardial CNP levels were elevated (2 to 3 times) in CHF patients compared with controls (P<0.05). A discrepancy therefore exists between circulating and local levels of CNP in CHF patients.
We have shown that in CHF patients, CNP levels are significantly increased in the CS compared with the aorta. This supports the hypothesis that CNP is produced directly in the myocardium, although it does not permit differentiation between the atrium and ventricle as the principal source. It is likely that the level within the CS (or general circulation) underestimates the CNP concentration in proximity to NPR-B receptors located on endothelial cells and myocardial tissue. It is therefore difficult to relate the degree of myocardial CNP spillover with functional effects.
In vitro studies have demonstrated marked augmentation of CNP secretion from cultured endothelial cells by mediators important in the pathogenesis of CHF, such as tumor necrosis factor, lipopolysaccharide, and BNP.19,20 Little is known about the role of hemodynamic factors in CNP release. In the present study, CS CNP levels correlated with PCWP. Although both may reflect the severity of myocardial dysfunction, it is tempting to speculate that myocardial CNP production occurs in response to elevated ventricular pressure filling pressure. Larger studies with subjects exposed to different PCWPs are required to verify this.
Locally produced CNP might affect cardiac function in several ways. Discrepant results have been seen in animal models: Exogenous CNP applied to dog right atrial preparations results in an enhanced inotropic effect,8 whereas a negative inotropic effect was demonstrated on rat papillary muscles.9 Myocardial CNP production may help to regulate local vascular tone in an attempt to optimize myocardial perfusion despite alterations in filling pressures. It may also inhibit myocardial ACE activity, as it has already been shown to do in the peripheral vasculature.
Borgeson et al21 showed that acute intravascular overload in dogs resulted in the expected increase in PCWP and plasma ANP but no change in plasma BNP and CNP levels. In contrast, a marked increase in urinary CNP but not ANP or BNP was seen. It appears that a differential release of natriuretic peptides from the myocardium and kidney occurs in response to alterations in ventricular filling pressures.
In conclusion, we have shown that in CHF, the heart produces CNP. Although further evaluation is required to define its full pathophysiological role in this condition, CNP may represent an important new local autocrine and/or endocrine mediator in the heart.
|
Acknowledgments |
|---|
Dr Kalra, Dr Bolger, and the Department of Clinical Cardiology are supported by the British Heart Foundation. Dr Kalra was previously supported by Wessex Heartbeat and the Waring Trust. Professor Coats is supported by the Viscount Royston Trust.
Received September 26, 2002; accepted October 15, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Wei CM, Aarhus LL, Miller VM, et al. The action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol. 1993; 264: H71–H73.[Medline] [Order article via Infotrieve]
2. Kalra PR, Anker SD, Struthers AD, et al. The role of CNP in cardiovascular medicine. Eur Heart J. 2001; 22: 997–1007.
3. Hunt PJ, Richards AM, Espiner EA, et al. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab. 1994; 78: 1428–435.[Abstract]
4. Burnett JC Jr, Kao PC, Hu DC. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986; 231: 1145–1147.
5. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991; 87: 1402–1412.[Medline] [Order article via Infotrieve]
6. Nunez DJR, Dickson CM, Brown KJ. Natriuretic peptide receptor mRNAs in the rat and human heart. J Clin Invest. 1992; 90: 1966–1971.[Medline] [Order article via Infotrieve]
7. Wei CM, Heublein DM, Perrella MA, et al. Natriuretic peptide system in human heart failure. Circulation. 1993; 88: 1004–1009.
8. Beaulieu P, Cardinal R, Page P, et al. Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs. Am J Physiol. 1997; 273: H1933–H1940.[Medline] [Order article via Infotrieve]
9. Brusq J-M, Mayoux E, Guigui L, et al. Effects of C-type natriuretic peptide on rat cardiac contractility. Br J Pharmacol. 1999; 128: 206–212.[CrossRef][Medline] [Order article via Infotrieve]
10. Cargill RI, Barr CS, Coutie WJ, et al. C-type natriuretic peptide levels in cor pulmonale and in congestive cardiac failure. Thorax. 1994; 49: 1247–1249.
11. Kalra PR, Anker SD, Coats AJS. Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res. 2001; 51: 495–509.
12. Stingo AJ, Clavell AL, Heublein DM, et al. Presence of C-type natriuretic peptide in cultured human endothelial cells and human plasma. Am J Physiol. 1992; 263: H1318–H1321.[Medline] [Order article via Infotrieve]
13. Suga S, Nakao K, Hosoda K, et al. Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology. 1992; 130: 229–239.
14. Davidson NC, Barr CS, Struthers AD. C-type natriuretic peptide: an endogenous inhibitor of vascular angiotensin converting enzyme activity. Circulation. 1996; 93: 1155–1159.
15. Almeida FM, Suzuki M, Scarborough RM, et al. Clearance function of type C receptors of atrial natriuretic factor in rats. Am J Physiol. 1989; 256: R469–R475.[Medline] [Order article via Infotrieve]
16. Soleilhac JM, Lucas E, Beaumont A, et al. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium. Mol Pharmacol. 1992; 41: 609–614.[Abstract]
17. Kenny AJ, Bourne A, Ingram J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase 24.11. Biochem J. 1993; 291: 83–88.[Medline] [Order article via Infotrieve]
18. Takahashi T, Allen PD, Izumo S. Expression of A-, B-, and C-type natriuretic peptide genes in failing and developing ventricles. Circ Res. 1992; 71: 9–17.
19. Suga S, Itoh H, Komatsu Y, et al. Cytokine-induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells: evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology. 1993; 133: 3038–3041.
20. Nazario B, Hu RM, Pedram A, et al. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest. 1995; 95: 1151–1157.[Medline] [Order article via Infotrieve]
21. Borgeson DD, Stevens TL, Heublein DM, et al. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism. Clin Sci. 1998; 95: 195–202.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  S. C. Palmer, T. C.R. Prickett, E. A. Espiner, T. G. Yandle, and A. M. Richards Regional Release and Clearance of C-Type Natriuretic Peptides in the Human Circulation and Relation to Cardiac Function Hypertension, September 1, 2009; 54(3): 612 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Heeb, R. S. Baker, C. Lam, M. Basu, W. Lubbers, J. Y. Duffy, and P. Eghtesady Role of Natriuretic Peptides in cGMP Production in Fetal Cardiac Bypass. Ann. Thorac. Surg., March 1, 2009; 87(3): 841 - 847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Nielsen, J. F. Rehfeld, and J. P. Goetze Mismeasure of C-Type Natriuretic Peptide Clin. Chem., January 1, 2008; 54(1): 225 - 227. [Full Text] [PDF]
|
|
|
|
 |
|
 W.H. Wilson Tang, G. S. Francis, D. A. Morrow, L. K. Newby, C. P. Cannon, R. L. Jesse, A. B. Storrow, R. H. Christenson, COMMITTEE MEMBERS, R. H. Christenson, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure Circulation, July 31, 2007; 116(5): e99 - e109. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Dickey, D. R. Flora, P. M. Bryan, X. Xu, Y. Chen, and L. R. Potter Differential Regulation of Membrane Guanylyl Cyclases in Congestive Heart Failure: Natriuretic Peptide Receptor (NPR)-B, Not NPR-A, Is the Predominant Natriuretic Peptide Receptor in the Failing Heart Endocrinology, July 1, 2007; 148(7): 3518 - 3522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lavi, J. P. McConnell, C. S. Rihal, A. Prasad, V. Mathew, L. O. Lerman, and A. Lerman Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans Circulation, May 29, 2007; 115(21): 2715 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. H. Christoffersen, M. Aplin, C. C. Strom, S. P. Sheikh, O. Skott, P. K. Busk, S. Haunso, and L. B. Nielsen Increased natriuretic peptide receptor A and C gene expression in rats with pressure-overload cardiac hypertrophy Am J Physiol Heart Circ Physiol, April 1, 2006; 290(4): H1635 - H1641. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Potter, S. Abbey-Hosch, and D. M. Dickey Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions Endocr. Rev., February 1, 2006; 27(1): 47 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nishikimi, N. Maeda, and H. Matsuoka The role of natriuretic peptides in cardioprotection Cardiovasc Res, February 1, 2006; 69(2): 318 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Del Ry, C. Passino, M. Maltinti, M. Emdin, and D. Giannessi C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity Eur J Heart Fail, December 1, 2005; 7(7): 1145 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Nielsen, J. F. Rehfeld, F. Pedersen, J. Kastrup, R. Videbaek, and J. P. Goetze Measurement of Pro-C-Type Natriuretic Peptide in Plasma Clin. Chem., November 1, 2005; 51(11): 2173 - 2176. [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Scotland, M. Cohen, P. Foster, M. Lovell, A. Mathur, A. Ahluwalia, and A. J. Hobbs C-type natriuretic peptide inhibits leukocyte recruitment and platelet-leukocyte interactions via suppression of P-selectin expression PNAS, October 4, 2005; 102(40): 14452 - 14457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pompilio and L. Sironi Invited commentary Ann. Thorac. Surg., October 1, 2005; 80(4): 1351 - 1352. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Soeki, I. Kishimoto, H. Okumura, T. Tokudome, T. Horio, K. Mori, and K. Kangawa C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction J. Am. Coll. Cardiol., February 15, 2005; 45(4): 608 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Goetze, J. F. Rehfeld, R. Videbaek, L. Friis-Hansen, and J. Kastrup B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts Eur J Heart Fail, January 1, 2005; 7(1): 69 - 74. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hobbs, P. Foster, C. Prescott, R. Scotland, and A. Ahluwalia Natriuretic Peptide Receptor-C Regulates Coronary Blood Flow and Prevents Myocardial Ischemia/Reperfusion Injury: Novel Cardioprotective Role for Endothelium-Derived C-Type Natriuretic Peptide Circulation, September 7, 2004; 110(10): 1231 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Potter CNP, Cardiac Natriuretic Peptide? Endocrinology, May 1, 2004; 145(5): 2129 - 2130. [Full Text] [PDF]
|
|
|
|
|
|
T. Tokudome, T. Horio, T. Soeki, K. Mori, I. Kishimoto, S.-i. Suga, F. Yoshihara, Y. Kawano, M. Kohno, and K. Kangawa Inhibitory Effect of C-Type Natriuretic Peptide (CNP) on Cultured Cardiac Myocyte Hypertrophy: Interference between CNP and Endothelin-1 Signaling Pathways Endocrinology, May 1, 2004; 145(5): 2131 - 2140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ruskoaho Cardiac Hormones as Diagnostic Tools in Heart Failure Endocr. Rev., June 1, 2003; 24(3): 341 - 356. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||